{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:06:47Z","timestamp":1793444807984,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcyt.2024.05.025","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:31:06Z","timestamp":1717720266000},"page":"1285-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A review and statistical analysis to identify and describe relationships between CQAs and CPPs of natural killer cell expansion processes"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-1265","authenticated-orcid":false,"given":"Valentin","family":"von Werz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Spadiut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-9374","authenticated-orcid":false,"given":"Bence","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.05.025_bib0001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1615\/CritRevOncog.2014010866","article-title":"NK cells and virus-related cancers","volume":"19","author":"Mishra","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12865-019-0326-8","article-title":"NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.coi.2006.05.002","article-title":"Natural killer cells as an initial defense against pathogens","volume":"18","author":"Lodoen","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0004","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1537-2995.2012.03724.x","article-title":"Natural killer cells: a review of manufacturing and clinical utility","volume":"53","author":"Koepsell","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0007","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12026-015-8664-y","article-title":"Practical NK cell phenotyping and variability in healthy adults","volume":"62","author":"Angelo","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02194782","article-title":"Studies on NK cell purification by negative selection in human peripheral blood","volume":"5","author":"Farace","year":"1992","journal-title":"Biotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13036-021-00264-7","article-title":"Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy","volume":"15","author":"Garcia-Aponte","year":"2021","journal-title":"J Biol Eng"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0011","doi-asserted-by":"crossref","first-page":"A.3b.1","DOI":"10.1002\/cptx.13","article-title":"Basic techniques in mammalian cell tissue culture","volume":"70","author":"Phelan","year":"2016","journal-title":"Curr Protoc Toxicol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0012","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00449-008-0295-4","article-title":"Kinetic analysis of hybridoma cells viability under mechanical shear stress with and without serum protection","volume":"32","author":"Legazpi","year":"2009","journal-title":"Bioprocess Biosyst Eng"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0013","first-page":"17","article-title":"Why do we still use serum in the production of biopharmaceuticals?","volume":"99","author":"Shah","year":"1999","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0014","doi-asserted-by":"crossref","first-page":"e21230","DOI":"10.1371\/journal.pone.0021230","article-title":"Differences between human plasma and serum metabolite profiles","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0015","first-page":"7","article-title":"Peak serum: implications of serum supply for cell therapy manufacturing","volume":"7","author":"Davie","year":"2012","journal-title":"Future Medicine"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-2776(04)86006-1","article-title":"Interleukin-2, interleukin-15, and their roles in human natural killer cells","volume":"86","author":"Becknell","year":"2005","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 \u2013 IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0018","first-page":"9016","article-title":"In vivo antitumor activity of interleukin 21 mediated by natural killer cells","volume":"63","author":"Wang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0019","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2003.08.039","article-title":"IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses","volume":"112","author":"Habib","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0020","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/eji.1830140409","article-title":"Mechanism of T lymphocyte activation by OKT3 antibodies. A general model for T cell induction","volume":"14","author":"Landegren","year":"1984","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0022","first-page":"5678","article-title":"Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy","volume":"14","author":"Yu","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0024","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V80.9.2221.2221","article-title":"Role of monocytes in the expansion of human activated natural killer cells","volume":"80","author":"Miller","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3109\/14653241003786155","article-title":"Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients","volume":"12","author":"Siegler","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0027","doi-asserted-by":"crossref","first-page":"383","DOI":"10.7150\/jca.2.383","article-title":"Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells","volume":"2","author":"Lundqvist","year":"2011","journal-title":"J Cancer"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0028","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcyt.2015.03.611","article-title":"Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy","volume":"17","author":"Granzin","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0031","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0032","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/bit.28086","article-title":"Differential effects on natural killer cell production by membrane-bound cytokine stimulations","volume":"119","author":"Chang","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/152581601750098471","article-title":"Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors","volume":"10","author":"Gazitt","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0034","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coviro.2011.11.003","article-title":"Virus disinfection mechanisms: the role of virus composition, structure, and function","volume":"2","author":"Wigginton","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0036","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.it.2011.05.002","article-title":"G-protein-coupled receptors in control of natural killer cell migration","volume":"32","author":"Walzer","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0037","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.coi.2007.04.004","article-title":"Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses","volume":"19","author":"Walzer","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0038","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0039","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0040","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/cells10061420","article-title":"NKG2D natural killer cell receptor\u2014a short description and potential clinical applications","volume":"10","author":"Siemaszko","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00005-023-00674-z","article-title":"Activating NKG2C receptor: functional characteristics and current strategies in clinical applications","volume":"71","author":"Siemaszko","year":"2023","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0042","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/icb.2013.95","article-title":"DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins","volume":"92","author":"de Andrade","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0043","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/cancers12071755","article-title":"Roles of NK cell receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in cancer","volume":"12","author":"Buller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0044","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0045","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0046","unstructured":"Heinisch O. Cochran WG. Sampling Techniques, 2. Aufl. John Wiley and Sons, New York, London 1963. Preis sBiometrische Zeitschrift19657203"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0047","unstructured":"Grafe AVollmar J.Small numbers in mutagenicity testsArch Toxicol1977382734"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0048","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/03610918008812164","article-title":"A table of normal integrals","volume":"9","author":"Owen","year":"1980","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0049","first-page":"e19561","article-title":"Perception of stretch marks risk factors among adults in Riyadh, Saudi Arabia","volume":"13","author":"Alageel","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0050","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3109\/14653249.2010.504770","article-title":"Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor","volume":"12","author":"Sutlu","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0051","doi-asserted-by":"crossref","first-page":"e20740","DOI":"10.1371\/journal.pone.0020740","article-title":"Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process","volume":"6","author":"Spanholtz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0052","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.4110\/in.2018.18.e31","article-title":"Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy","volume":"18","author":"Min","year":"2018","journal-title":"Immune Netw"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0053","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","article-title":"Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0054","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbmt.2014.12.037","article-title":"Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach","volume":"21","author":"Oyer","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0055","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2007-09-110312","article-title":"Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components","volume":"111","author":"Alici","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0056","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Kloss","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0057","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/hgtb.2019.039","article-title":"Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering","volume":"30","author":"Oberschmidt","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0058","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-017-2055-2","article-title":"Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies","volume":"67","author":"Nowakowska","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0059","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/15258160260194794","article-title":"Large-scale generation of natural killer lymphocytes for clinical application","volume":"11","author":"Luhm","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fbioe.2019.00194","article-title":"Mass production of highly active NK cells for cancer immunotherapy in a GMP conform perfusion bioreactor","volume":"7","author":"Broker","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0061","doi-asserted-by":"crossref","first-page":"14916","DOI":"10.1038\/s41598-019-51287-6","article-title":"Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells","volume":"9","author":"Ojo","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0062","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jprot.2013.06.024","article-title":"Differential expression of proteins in naive and IL-2 stimulated primary human NK cells identified by global proteomic analysis","volume":"91","author":"Ma","year":"2013","journal-title":"J Proteomics"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0063","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/CJI.0b013e3181f71b81","article-title":"Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients","volume":"33","author":"Park","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0064","doi-asserted-by":"crossref","first-page":"e53611","DOI":"10.1371\/journal.pone.0053611","article-title":"GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo","volume":"8","author":"Lim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1756-9966-29-134","article-title":"Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity","volume":"29","author":"Voskens","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0066","first-page":"464","article-title":"A good manufacturing practice method to ex vivo expand natural killer cells for clinical use","volume":"13","author":"Torelli","year":"2015","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0067","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-014-1614-z","article-title":"Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients","volume":"64","author":"Peragine","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0068","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/0008-5472.CAN-12-2893","article-title":"Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy","volume":"73","author":"Lim","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0069","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0198-8859(01)00313-5","article-title":"A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells","volume":"62","author":"Carlens","year":"2001","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14653240310004548","article-title":"Ex vivo expansion of natural killer cells for clinical applications","volume":"6","author":"Klingemann","year":"2004","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0071","doi-asserted-by":"crossref","first-page":"e57922","DOI":"10.1371\/journal.pone.0057922","article-title":"Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies","volume":"8","author":"Besser","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0072","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0198-8859(01)00313-5","article-title":"A new method for in vitro expansion of cytotoxic human CD3\u2212CD56+ natural killer cells","volume":"62","author":"Carlens","year":"2001","journal-title":"Human Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0073","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-1759(94)90084-1","article-title":"Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy","volume":"167","author":"Freedman","year":"1994","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0074","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/stem.5530120502","article-title":"The activation antigen CD69","volume":"12","author":"Ziegler","year":"1996","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0075","article-title":"Potentiating the large-scale expansion and engineering of peripheral blood-derived CAR NK cells for off-the-shelf application","volume":"9","author":"Whang","year":"2021","journal-title":"J. Immunotherap. Cancer."},{"key":"10.1016\/j.jcyt.2024.05.025_bib0076","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-2005-872520","article-title":"Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children","volume":"217","author":"Koehl","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0077","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-12-reviews3014","article-title":"Granzymes: a family of lymphocyte granule serine proteases","volume":"2","author":"Trapani","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0078","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/82732","article-title":"Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule","volume":"1","author":"Holler","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0079","first-page":"1138","article-title":"Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis","volume":"61","author":"Seol","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00262-002-0298-y","article-title":"Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants","volume":"51","author":"Gritzapis","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0081","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0082","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.molmed.2016.05.007","article-title":"Exercise-dependent regulation of NK cells in cancer protection","volume":"22","author":"Idorn","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0083","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mrm.22968","article-title":"Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model","volume":"66","author":"Liu","year":"2011","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0084","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1002\/cti2.1151","article-title":"Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia","volume":"9","author":"Foley","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jcyt.2024.05.025_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765705","article-title":"Making a killer: selecting the optimal natural killer cells for improved immunotherapies","volume":"12","author":"Barnes","year":"2021","journal-title":"Front Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:10:53Z","timestamp":1728659453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924007333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1465324924007333"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.025","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review and statistical analysis to identify and describe relationships between CQAs and CPPs of natural killer cell expansion processes","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}